Europe Fill Finish Pharmaceutical Contract Manufacturing Market Size, Share & Trends Analysis Report By Product (Prefilled Syringes, Vials, Cartridges), By Molecule, By End Use, By Region, And Segment Forecasts, 2025 - 2030

Europe Fill Finish Pharmaceutical Contract Manufacturing Market Size, Share & Trends Analysis Report By Product (Prefilled Syringes, Vials, Cartridges), By Molecule, By End Use, By Region, And Segment Forecasts, 2025 - 2030


3D Medical Imaging Devices Market Growth & Trends

The global 3D medical imaging devices market is estimated to reach USD 20.31 billion by 2030, registering a CAGR of 8.11% from 2025 to 2030, according to a new report by Grand View Research, Inc. The market is driven by the increasing prevalence of cardiovascular diseases, Alzheimer’s, cancer, and other chronic diseases. Moreover, the rise in healthcare expenditure across developed economies and rapid technological advancements are some of the other factors responsible for the market growth.

Furthermore, continuous advancements in imaging technology play an important role in driving market growth. Innovations in modalities such as computed tomography (CT), magnetic resonance imaging (MRI), and ultrasound have led to higher-resolution 3D imaging, allowing for more precise and detailed visualization of anatomical structures and pathological conditions. Healthcare providers are increasingly seeking state-of-the-art imaging equipment, which fuels the demand for 3D medical imaging devices.

Competition among medical device manufacturers and the introduction of new and innovative 3D imaging devices are driving market growth as companies strive to offer cutting-edge solutions. For instance, in August 2023, GigXR, Inc. launched an application, XR Library, which is driven by INTRAVISION XR, as part of its immersive learning platform. This innovative application provides a comprehensive collection of 3D medical visuals derived from CT and MRI scans. Similarly, in September 2022, GE Healthcare received FDA authorization for its AIR Recon, an advanced 3D and motion-insensitive imaging applications. This development promises to enhance the overall quality of MRI images while providing a more enhanced experience for patients. These factors are further contributing to market growth.

3D Medical Imaging Devices Market Report Highlights
  • In terms of applications, the oncology segment dominated the market in 2024 with a revenue share of more than 33%. The growth of the segment is attributed to the increasing prevalence of cancer globally.
  • In terms of end-use, the hospitals segment dominated the market in 2024 with the largest revenue share of 48%. Hospitals offer a wide range of medical services, from routine check-ups to complex surgeries and specialized treatments. These factors have boosted the demand for medical imaging devices.
  • Based on region, North America held the largest revenue share of about 35.8% in 2024. The growth is attributed to the growing adoption of minimally invasive surgeries and increasing demand for novel technologies.
Please note The report will be delivered in 2-3 business days upon order notification.


Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Product
1.2.2. Molecule
1.2.3. End Use
1.3. Estimates and Forecast Timeline
1.4. Research Methodology
1.5. Information Procurement
1.5.1. Purchased Database
1.5.2. GVR’s Internal Database
1.5.3. Secondary Sources
1.5.4. Primary Research
1.6. Information Analysis
1.6.1. Data Analysis Models
1.7. Market Formulation & Data Visualization
1.8. Model Details
1.8.1. Commodity Flow Analysis
1.9. List of Secondary Sources
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Snapshot
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
Chapter 3. Europe Fill-finish Pharmaceutical Contract Manufacturing Market Variables, Trends, & Scope
3.1. Market Lineage Outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.2. Market Restraint Analysis
3.3. Business Environment Analysis
3.3.1. Industry Analysis - Porter’s Five Forces Analysis
3.3.1.1. Supplier Power
3.3.1.2. Buyer Power
3.3.1.3. Substitution Threat
3.3.1.4. Threat of New Entrants
3.3.1.5. Competitive Rivalry
3.3.2. PESTLE Analysis
Chapter 4. Europe Fill-finish Pharmaceutical Contract Manufacturing Market: Product Business Analysis
4.1. Product Market Share, 2024 & 2030
4.2. Product Segment Dashboard
4.3. Market Size & Forecasts and Trend Analysis, by Product, 2018 to 2030 (USD Million)
4.4. Prefilled Syringes
4.4.1. Prefilled Syringes Market, 2018 - 2030 (USD Million)
4.5. Vials
4.5.1. Vials Market, 2018 - 2030 (USD Million)
4.6. Cartridges
4.6.1. Cartridges Market, 2018 - 2030 (USD Million)
4.7. Others
4.7.1. Others Market, 2018 - 2030 (USD Million)
Chapter 5. Europe Fill-finish Pharmaceutical Contract Manufacturing Market: Molecule Business Analysis
5.1. Molecule Market Share, 2024 & 2030
5.2. Molecule Segment Dashboard
5.3. Market Size & Forecasts and Trend Analysis, by Molecule, 2018 to 2030 (USD Million)
5.4. Large Molecules
5.4.1. Large Molecules Market, 2018 - 2030 (USD Million)
5.5. Small Molecules
5.5.1. Small Molecules Market, 2018 - 2030 (USD Million)
Chapter 6. Europe Fill-finish Pharmaceutical Contract Manufacturing Market: End Use Business Analysis
6.1. End Use Market Share, 2024 & 2030
6.2. End Use Segment Dashboard
6.3. Market Size & Forecasts and Trend Analysis, by End Use, 2018 to 2030 (USD Million)
6.4. Biopharmaceutical Companies
6.4.1. Biopharmaceutical Companies Market, 2018 - 2030 (USD Million)
6.5. Pharmaceutical Companies
6.5.1. Pharmaceutical Companies Market, 2018 - 2030 (USD Million)
Chapter 7. Europe Fill-finish Pharmaceutical Contract Manufacturing Market: Country Estimates & Trend Analysis by Product, Molecule, and End Use
7.1. Regional Market Share Analysis, 2024 & 2030
7.2. Regional Market Dashboard
7.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
7.4. UK
7.4.1. Key Country Dynamics
7.4.2. Regulatory Framework
7.4.3. Competitive Insights
7.4.4. UK Fill-finish Pharmaceutical Contract Manufacturing Market Estimates And Forecasts, 2018 - 2030 (USD Million)
7.5. Germany
7.5.1. Key Country Dynamics
7.5.2. Regulatory Framework
7.5.3. Competitive Insights
7.5.4. Germany Fill-finish Pharmaceutical Contract Manufacturing Market Estimates And Forecasts, 2018 - 2030 (USD Million)
7.6. France
7.6.1. Key Country Dynamics
7.6.2. Regulatory Framework
7.6.3. Competitive Insights
7.6.4. France Fill-finish Pharmaceutical Contract Manufacturing Market Estimates And Forecasts, 2018 - 2030 (USD Million)
7.7. Italy
7.7.1. Key Country Dynamics
7.7.2. Regulatory Framework
7.7.3. Competitive Insights
7.7.4. Italy Fill-finish Pharmaceutical Contract Manufacturing Market Estimates And Forecasts, 2018 - 2030 (USD Million)
7.8. Spain
7.8.1. Key Country Dynamics
7.8.2. Regulatory Framework
7.8.3. Competitive Insights
7.8.4. Spain Fill-finish Pharmaceutical Contract Manufacturing Market Estimates And Forecasts, 2018 - 2030 (USD Million)
7.9. Norway
7.9.1. Key Country Dynamics
7.9.2. Regulatory Framework
7.9.3. Competitive Insights
7.9.4. Norway Fill-finish Pharmaceutical Contract Manufacturing Market Estimates And Forecasts, 2018 - 2030 (USD Million)
7.10. Denmark
7.10.1. Key Country Dynamics
7.10.2. Regulatory Framework
7.10.3. Competitive Insights
7.10.4. Denmark Fill-finish Pharmaceutical Contract Manufacturing Market Estimates And Forecasts, 2018 - 2030 (USD Million)
7.11. Sweden
7.11.1. Key Country Dynamics
7.11.2. Regulatory Framework
7.11.3. Competitive Insights
7.11.4. Sweden Fill-finish Pharmaceutical Contract Manufacturing Market Estimates And Forecasts, 2018 - 2030 (USD Million)
Chapter 8. Competitive Landscape
8.1. Participant Overview
8.2. Company Market Position Analysis
8.3. Company Categorization
8.4. Strategy Mapping
8.5. Company Profiles/Listing
8.5.1. Thermo Fisher Scientific Inc.
8.5.1.1. Overview
8.5.1.2. Financial Performance
8.5.1.3. Product Benchmarking
8.5.1.4. Strategic Initiatives
8.5.2. Sartorius AG
8.5.2.1. Overview
8.5.2.2. Financial Performance
8.5.2.3. Product Benchmarking
8.5.2.4. Strategic Initiatives
8.5.3. Boehringer Ingelheim International GmbH
8.5.3.1. Overview
8.5.3.2. Financial Performance
8.5.3.3. Product Benchmarking
8.5.3.4. Strategic Initiatives
8.5.4. Catalent, Inc (acquired by Novo Holdings A/S)
8.5.4.1. Overview
8.5.4.2. Financial Performance
8.5.4.3. Product Benchmarking
8.5.4.4. Strategic Initiatives
8.5.5. Societal CDMO (Recro Pharma, Inc)
8.5.5.1. Overview
8.5.5.2. Financial Performance
8.5.5.3. Product Benchmarking
8.5.5.4. Strategic Initiatives
8.5.6. Baxter
8.5.6.1. Overview
8.5.6.2. Financial Performance
8.5.6.3. Product Benchmarking
8.5.6.4. Strategic Initiatives
8.5.7. Eurofins Scientific
8.5.7.1. Overview
8.5.7.2. Financial Performance
8.5.7.3. Product Benchmarking
8.5.7.4. Strategic Initiatives
8.5.8. Symbiosis Pharmaceutical Services Ltd
8.5.8.1. Overview
8.5.8.2. Financial Performance
8.5.8.3. Product Benchmarking
8.5.8.4. Strategic Initiatives
8.5.9. MabPlex International Co. Ltd.
8.5.9.1. Overview
8.5.9.2. Financial Performance
8.5.9.3. Product Benchmarking
8.5.9.4. Strategic Initiatives
8.5.10. Recipharm AB
8.5.10.1. Overview
8.5.10.2. Financial Performance
8.5.10.3. Product Benchmarking
8.5.10.4. Strategic Initiatives
8.5.11. Fresenius Kabi, USA LLC
8.5.11.1. Overview
8.5.11.2. Financial Performance
8.5.11.3. Product Benchmarking
8.5.11.4. Strategic Initiatives
8.5.12. Lonza
8.5.12.1. Overview
8.5.12.2. Financial Performance
8.5.12.3. Product Benchmarking
8.5.12.4. Strategic Initiatives

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings